Thank you Misiu, and is a valid question: how long before we know Leronlimab is working??
In a related subject, link to an interesting presentation (Memorial Sloan Kettering) about Basket trials as we are now embarqed upon one. Things are a bit more complicated than a trial for one indication, of course, but it has its advantages as well.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559900/
Slide 25 in PDF presentation offers a possible design for a basket trial (this is an example presented in the link) with some data:
• It is possible to reduce the number of patients needed for basket trials by sharing information across baskets
• Sample size reductions of ~10% - 30% depending on the
homogeneity of the treatment effect
• Price to pay: if the treatment works in only one basket
information sharing requires ~5 %- 10% more patients
• Considering the general premise of targeted treatment this is a
modest price to pay for the potential gains
The article discusses also how data from one basket can be taken into account for another one and also trial designs (parallel, aggregation). This is important as we have already mTNBC data and soon more plus some other indications (I would think prostate and colon will be included).
If Leronlimab works well we will be soon entering in this area when the drug of the century enters the stage with multiple cancer indications and Keytruda (or Humira) will bow to Leronlimab
as the most sold one.
In a related subject, link to an interesting presentation (Memorial Sloan Kettering) about Basket trials as we are now embarqed upon one. Things are a bit more complicated than a trial for one indication, of course, but it has its advantages as well.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5559900/
Slide 25 in PDF presentation offers a possible design for a basket trial (this is an example presented in the link) with some data:
• It is possible to reduce the number of patients needed for basket trials by sharing information across baskets
• Sample size reductions of ~10% - 30% depending on the
homogeneity of the treatment effect
• Price to pay: if the treatment works in only one basket
information sharing requires ~5 %- 10% more patients
• Considering the general premise of targeted treatment this is a
modest price to pay for the potential gains
The article discusses also how data from one basket can be taken into account for another one and also trial designs (parallel, aggregation). This is important as we have already mTNBC data and soon more plus some other indications (I would think prostate and colon will be included).
If Leronlimab works well we will be soon entering in this area when the drug of the century enters the stage with multiple cancer indications and Keytruda (or Humira) will bow to Leronlimab
as the most sold one.
1
